Study claims Covaxin has ability to neutralise new UK Covid strain
Reacting to the study's claims, ICMR tweeted Covaxin has equivalent immunogenicity against the UK-variant and circulating strains of SARS-COV-2 in India.
advertisement
Covaxin is being developed and manufactured by Bharat Biotech in collaboration with ICMR. (Representational image)
Covaxin, the Covid-19 vaccine candidate developed by Bharat Biotech, has the ability to neutralise the new UK variant of the virus causing Covid-19, according to a preprint review by bioRxiv, a free online archive and distribution service for unpublished preprints in the life sciences.
The archives operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution in New York.